source
- Capricor shareholders face board overhaul push as investors demand meeting and capital-preservation plan amid DMD cell therapy delayKaos Capital, describing itself as a significant shareholder of Capricor Therapeutics, sent a letter to fellow investors calling for an immediate meeting, a change of the board, and a capital-prese…
- Activist Kaos Capital pushes governance overhaul at Capricor ahead of FDA Duchenne decisionActivist investor Kaos Capital has sent a letter to Capricor Therapeutics shareholders demanding a “governance reset.” The firm asks for a meeting to nominate two independent directors, create an M…